Zepbound Patients Fear Losing Coverage After CVS Deal for Wegovy

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now she fears a deal struck between CVS Health Corp. and Novo Nordisk A/S will undo all that progress.

CVS’s drug-benefits unit, known as Caremark, earlier this month negotiated a deal to make Novo’s Wegovy more widely available to its customers — knocking Eli Lilly & Co.’s Zepbound off its list of preferred drugs. Already, patients such as Stange are receiving letters indicating their costs may go up.

“Starting July 1, 2025, your current medication won’t be covered and you’ll ...